Position in ROIV
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$6,759
+$2,134 QoQ
Shares Held
191
+14.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#98
of 134 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RAFFA WEALTH MANAGEMENT, LLC holds $112,928 across 35 Biotechnology names. ROIV ranks #5 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
66 | $32,784 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
25 | $15,588 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
46 | $8,614 | |
| 4 | PTGX |
Protagonist Therapeutics, Inc
|
60 | $7,354 | |
| 5 | ROIV |
Roivant Sciences Ltd.
This page
|
191 | $6,759 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
21 | $6,321 | |
| 7 | ARGX |
Argenx SE
|
5 | $4,638 | |
| 8 | MRNA |
Moderna, Inc.
|
63 | $4,411 |
All Filings in ROIV
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,759 | 191 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $4,625 | 167 | Shares | Sole | 2026-07-27 | |
| 2025-12-31 | $3,472 | 160 | Shares | Sole | 2026-07-27 | |
| 2025-09-30 | $2,420 | 160 | Shares | Sole | 2026-07-27 | |
| 2025-06-30 | $1,803 | 160 | Shares | Sole | 2026-07-27 | |
| 2025-03-31 | $1,614 | 160 | Shares | Sole | 2026-07-27 | |
| 2024-12-31 | $1,892 | 160 | Shares | Sole | 2026-07-27 | |
| 2024-09-30 | $1,846 | 160 | Shares | Sole | 2026-07-27 | |
| 2024-06-30 | $1,691 | 160 | Shares | Sole | 2026-07-27 | |
| 2024-03-31 | $1,686 | 160 | Shares | Sole | 2026-07-27 | |
| 2023-12-31 | $1,796 | 160 | Shares | Sole | 2026-07-27 | |
| 2023-09-30 | $1,868 | 160 | Shares | Sole | 2026-07-27 | |
| No filing history on record for this holder in this stock. | ||||||